Paternal Valproate Use Before Conception Not Linked

Does a Father's Valproate Use Raise a Child's Autism or ADHD Risk?

Valproate is an established antiseizure medicine that is also used for certain other neurological and psychiatric conditions. Researchers examined whether fathers taking the drug before conception were more likely to have children diagnosed with neurodevelopmental conditions, including autism and attention-deficit/hyperactivity disorder. The analysis did not identify such an association.

The result addresses paternal exposure, meaning medicine taken by the father around the period when sperm develop. It must not be confused with valproate use during pregnancy, which carries well-established risks of congenital abnormalities and developmental problems because the fetus is directly exposed. The new finding does not change pregnancy-related safety restrictions for patients who could become pregnant.

How Should Families Interpret a No-Association Finding?

Observational studies can compare outcomes in large groups without intentionally exposing families to a medicine, making them important for investigating uncommon or delayed effects. However, they can be affected by differences in diagnoses, medication adherence, dose, underlying illness and other parental characteristics. A result showing no association means that the study did not detect an elevated risk; it does not establish that every possible effect has been ruled out.

Regulators previously introduced precautions after other observational evidence suggested a possible neurodevelopmental risk following paternal exposure. The European Medicines Agency advised clinicians to discuss contraception, treatment alternatives and pregnancy planning with male patients using valproate. Newer reassuring evidence should therefore be considered alongside the total body of research rather than treated as a stand-alone reversal of existing guidance.

Should Men Stop Valproate When Planning a Pregnancy?

Suddenly discontinuing an effective antiseizure medicine can lead to breakthrough seizures, injuries or status epilepticus. A clinician can review why valproate was prescribed, how well it is controlling the condition, the dose being used and whether another medicine could provide comparable control. For some patients, continuing treatment may be safer than changing a stable regimen.

European guidance has advised male patients and their partners to use effective contraception during treatment and for three months after stopping, while also avoiding sperm donation during that period. Recommendations may evolve as regulators assess new evidence, so people planning a pregnancy should request a medication review and follow guidance applicable in their country.